Continuous Low-Dose (Metronomic) Chemotherapy on Rat Prostate Tumors Evaluated Using MRI In Vivo and Comparison with Histology  by Zhao, Dawen et al.
Continuous Low-Dose (Metronomic) Chemotherapy on Rat
Prostate Tumors Evaluated Using MRI In Vivo and
Comparison with Histology1
Dawen Zhao, Lan Jiang, Eric W. Hahn and Ralph P. Mason*
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Abstract
Continuous low-dose (metronomic) therapy, based on
cyclophosphamide (CTX) combined with thalidomide
(Tha), was evaluated on Dunning prostate R3327-AT1
rat tumors. Significantly delayed tumor growth (P <
.001) was observed with oral CTX alone at a low dose
(metronomic cyclophosphamide or M-CTX; 30 mg/kg
per day) or combined with Tha. To investigate dynamic
changes in tumor physiology during early stages of
treatment, magnetic resonance imaging (MRI) was ap-
plied before and during the M-CTX or M-CTX + Tha
therapy. Dynamic contrast-enhanced MRI revealed
significant changes in the tumor center by day 3 (P <
.01); by day 7, only a thin peripheral tumor region
showed high signal enhancement. There was a signifi-
cant correlation between poorly enhancing fraction on
day 7 and ultimate tumor growth delay (P < .02). The
apparent transverse relaxation rate (R2*) showed sim-
ilar baseline tumor heterogeneity, but no obvious
changes with growth or therapy. Histology confirmed
substantial necrosis in the tumor center, leaving a thin
live peripheral rim. Immunohistochemistry showed a
significant increase in vascular endothelial growth fac-
tor, and apoptotic tumor and vascular endothelial
cells. These results show the efficacy of the metro-
nomic CTX ± Tha for delaying tumor growth and
indicate that MRI provides insights into the mode of
action and early indication of efficacy.
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Introduction
Recent studies show that extended continuous administra-
tion of certain cytotoxic agents at very low doses, so-called
‘‘metronomic’’ chemotherapy, generates antiangiogenic
activity [1–5]. Furthermore, continuous low-dose chemo-
therapy combined with an antiangiogenic agent effectively
circumvented acquired drug resistance [6]. Previous tests
have generally used human tumor xenografts in immuno-
compromised mice or fast-growing rodent tumors. The cur-
rent study examines this new treatment strategy in a slower-
growing tumor, the anaplastic Dunning R3327-AT1 rat pros-
tate tumor implanted syngeneically in Copenhagen rats. The
popular chemotherapeutic agent, cyclophosphamide (CTX)
was chosen because it is one of the most widely used alkyl-
ating drugs. CTX is also effective against a wide variety of
cancers including androgen-independent prostate cancer
(AIPC), and recent reports indicated efficacy when it was ad-
ministered continuously at low doses [7,8]. Thalidomide (Tha)
was also used because it has recently been shown to exhibit
antiangiogenic activity [9–11].
This study had two primary goals: the first was to determine
whether metronomic cyclophosphamide (M-CTX), with or with-
out the addition of Tha, could significantly delay the growth
of the syngeneic prostate tumor in an immunocompetent rat.
The second goal was to determine whether magnetic reso-
nance imaging (MRI) could delineate sequential physiological
changes, especially in the vasculature during the early stages
of treatment. MRI permits noninvasive evaluation of tumor
physiology, potentially revealing treatment-induced changes
occurring prior to overt changes in tumor size [12,13]. Dynamic
contrast-enhanced (DCE) MRI based on the transport of
gadolinium DTPA (Gd-DTPA) has been widely used in animal
and clinical studies to provide an indication of tumor perfusion
and permeability [14–17]. Blood oxygen level–dependent
(BOLD) contrast in 1H MRI has also been applied to assess
acute response to drugs [17–19].
Abbreviations: MRI, magnetic resonance imaging; DCE MRI, dynamic contrast-enhanced
MRI; BOLD MRI, blood oxygen level – dependent MRI; R2*, transverse relaxation rate; AUC,
area under the signal intensity – time curve; CTX, cyclophosphamide; Tha, thalidomide; M-CTX,
metronomic cyclophosphamide; MTD, maximum tolerated dose; AIPC, androgen-independent
prostate cancer
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Methods
Tumor Model
Syngeneic Dunning prostate R3327-AT1 rat tumors were
implanted in a skin pedicle surgically created on the foreback
of adult male Copenhagen 2331 rats (f250 g; Harlan, In-
dianapolis, IN), as described in detail previously [20]. Cells
were originally obtained from Dr. J. T. Isaacs (Johns Hopkins,
Baltimore, MD) and provided to us by Dr. P. Peschke (DKFZ,
Heidelberg,Germany).Wechose theAT1subline because it is
slower-growing (VDT = 5.2 days) and, normally, the tu-
mor does not develop a central necrosis [21,22]. Experi-
ments were approved by the Institutional Animal Care and
Use Committee.
Drugs and Treatment Proztocol
Tumor-bearing rats were divided into five groups, and
treatment was initiated when tumor size reached f1 cm
diameter—group 1: untreated control (n = 6); group 2: Tha
(Tocris Cookson, Inc., Ellisville, MO) at 60 mg/kg, intraperi-
toneally (i.p.), twice per week (n = 6). Tha was prepared in
saline plus a few drops of DMSO with rapid stirring and gen-
tle warming tof45jC; group 3: standard CTX (SigmaChem-
ical Co., St. Louis, MO) therapy at 150 mg/kg, i.p., twice per
week (n = 6); group 4: continuous low-dose cyclophospha-
mide (M-CTX) dissolved in distilled water at 30 mg/kg, p.o.,
daily (n = 12), as suggested by the dosing schedule of Man
et al. [3]. Daily water consumption by the Copenhagen rats
was monitored for five consecutive days and was found to
be highly consistent with a volumef30ml/day. Subgroup 4a
(n = 6) was used for growth delay study, whereas sub-
group 4b (n = 6) was monitored by MRI and sacrificed on
day 7; group 5: combination of low-dose M-CTX (30 mg/kg,
p.o., daily) with Tha (60 mg/kg, i.p., twice per week, n = 13).
Subgroup 5a (n = 7) was observed for 42 days, whereas
those in subgroup 5b (n = 6) were sacrificed following MRI
on day 7. Tumor size was measured every 3 days using a
caliper and volume was calculated as p/6abc, where a, b,
and c are three respective dimensions.
MRI Experiments
MRI was performed on all the rats in subgroup 4b (n = 6),
group 5 (n = 13), and selected controls (n = 3) using a 4.7-T
horizontal boremagnet with a Varian Unity Inova system (Palo
Alto, CA). TheM-CTX–treated subgroup 4b and the M-CTX +
Tha–treated subgroup 5a were studied before treatment
(day 0) and 7 days after treatment, whereas the six rats
treated with M-CTX + Tha (subgroup 5b) were scanned more
frequently (days 0, 1, 3, and 7) to detect earlier changes in
response to treatment. Each rat was anesthetized with
ketamine hydrochloride (200 ml; 100 mg/ml) as a relaxant
(i.p.) and maintained under general anesthesia (air and 1%
isoflurane). The tail vein was catheterized using a 27-G
butterfly (Abbott Laboratories, Abbott Park, IL) for contrast
agent administration. Each animal was placed on its side in
a cradle with a thermal blanket to maintain body tempera-
ture. Typically, three 2-mm–thick cross sections parallel to the
animal were selected from a T1-weighted scout image to rep-
resent tumor regions of surface, center, and base (adjacent to
the animal). The following MRI investigations were applied.
R2* measurements Multigradient echo (MGRE) images
with eight echoes [repetition time (TR) = 195 milliseconds,
initial echo time (TE) = 7 milliseconds, echo spacing = 6 milli-
seconds, flip angle = 45j, field of view = 40 40mm,matrix =
128  128] were acquired simultaneously on the three
2-mm– thick slices with a total acquisition time of 6 minutes,
40 seconds. The transverse relaxation rate (R2*) map of
each section was generated using all eight images with
variable echo time by fitting an exponential model on a
voxel-by-voxel basis. Mean R2* for each tumor was obtained
by averaging the value from each of the three sections.
DCE MRI DCE MRI was performed on the same slices
using T1-weighted spin-echo images (TR = 220 milliseconds,
TE = 16 milliseconds, field of view = 40  40 mm, matrix =
128 128, two acquisitions, voxel size = 2.0 0.3 0.3 mm,
total time for three slices = 59 seconds). A baseline was
measured for 3 minutes and then a bolus of Gd-DTPA-BMA
(125 ml of 0.1 mmol/kg Omniscan; Amersham Health, Inc.,
Princeton, NJ) was injected through the tail vein catheter
in situ by hand over 1 second and continuous images
were acquired for 10 minutes. Data were processed on a
voxel-by-voxel basis using IDL 5.3/5.4 (Research Systems,
Boulder, CO). In addition to global mean signal intensity,
data were analyzed separately for center and periphery, rep-
resented by a 1- to 2-mm–thick rim around the whole
tumor. Following Gd-DTPA-BMA injection, signal intensity
versus time curves were plotted and relative signal inten-
sity changes (DSI) of each tumor voxel were analyzed
using the equation: (DSI) = (SIE  SIb)/SIb, where SIE re-
fers to enhanced signal intensity in the voxel and SIb is
defined as the average of the baseline images. The area
under the signal intensity– time curve (AUC) was inte-
grated as AUC60;120;180 ¼ m
t¼60;12;180
0
DSIdt
t . Although AUC values
were compared for each time point, all presented data are
for AUC180.
Histology and Immunohistochemistry
Following MRI on day 7, three tumors from each of groups
1, 4b, and 5b were prepared for sacrifice and histologic
evaluation. The hypoxia marker, pimonidazole hydrochloride
(60 mg/kg, Hypoxyprobe-1; NPI, Inc., Belmont, MA) was in-
jected into the tail vein to assess tumor hypoxia. Ninety
minutes later, rats were anesthetized and perfused for
20 min with physiological saline containing 5 mM CaCl2
[23]. Tumors were excised and cut into half through the
center of the tumor, corresponding to the central MRI slice.
Tumor tissues were fixed in 10% formalin or immediately
immersed in liquid nitrogen and stored at 80jC. For H&E
staining and immunohistochemistry for apoptosis, hypoxia,
and vascular endothelial growth factor (VEGF), the formalin-
fixed tissues were embedded in paraffin and sectioned
(4 mm), whereas cryostat sections (6 mm thick) were used
for vascular endothelium (anti-CD31) staining. The paraffin
sections were treated in boiling citrate buffer (0.1 M, pH 6.0)
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for 15 minutes and hydrated using xylene and ethanol prior
to immunostaining.
Necrosis Necrotic tumor regions were identified on the
H&E–stained slides of the central tumor slice examined
under low magnification (2 objective). Optical fields (f30)
in each section were captured by a digital camera and pro-
cessed using Metaview software (Universal Imaging Corpo-
ration, West Chester, PA). The proportion of necrotic areas
(% necrosis) was calculated as the sum of all necrotic areas
divided by the total area  100.
Apoptosis Apoptotic cells were detected using anti–
caspase-3 polyclonal antibody (1:100; Promega, Madison,
WI) with overnight incubation at 4jC and secondary horse-
radish peroxidase (HRP)–conjugated goat antirabbit sec-
ondary antibody (1:100 dilution; Serotec, Raleigh, NC) for
1 hour at 37jC.
VEGF Primary anti-VEGF(147) polyclonal antibody (1:100;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and HRP-
conjugated goat antirabbit secondary antibody (1:100)
were used.
Hypoxia Hypoxic regions were detected using monoclo-
nal antibody Mab1 (1:100; NPI, Inc.) and HRP-conjugated
goat antimouse secondary antibody (1:100 dilution; Sero-
tec). Hypoxic fraction was determined as an area positively
stained for pimonidazole relative to the total tissue area.
Necrotic regions were excluded in this analysis.
Blood vessel density The frozen sections were incubated
with mouse antirat CD31 monoclonal antibody (1:20; Serotec)
for 2 hours, and then FITC-conjugated goat antimouse sec-
ondary antibody (1:100 dilution; Jackson Immunoresearch
Laboratories,West Grove, PA) for 1 hour at 37jC. Aftermount-
ing with Vectorshield medium (Vector Laboratories, Burlin-
game, CA), the slides were observed under green fluo-
rescence (450–490 nm excitation). Vascular density of
peripheral tumor regions was evaluated using the ‘‘hot spot’’
technique, as described by Weidner [24]. The five most vascu-
larized areas in each tumor were selected under low magnifi-
cation (10). Vascular density was determined by counting the
total number of structures positive forCD31using20objective
(area 0.079 mm2) and by calculating the mean number of
vessels per square millimeter.
Statistical Analysis
Statistical significance was assessed using an analysis of
variance (ANOVA) on the basis of Scheffe’s F test (Statview;
SAS Institute, Inc., Cary, NC) or Student’s t tests.
Results
The conventional MTD of CTX (150 mg/kg, i.p.) significantly
delayed tumor growth, but there was extreme toxicity result-
ing in severe body weight loss and animal death after three
doses (3 150 mg/kg, P < .01). By contrast, no obvious side
effects were observed in the rats treated with the low-dose
M-CTX (30 mg/kg) alone or combined M-CTX + Tha. Signifi-
cant tumor growth delay was observed for both groups 4
(P < .01 by day 3) and 5 (P < .01 by day 3), compared with the
untreated control tumors (Figure 1); after 10 days, the growth
delay was not significantly less than group 3. Tumors in
group 2 also showed significantly delayed growth by day 7,
compared with the control tumors (P < .05).
R2* maps revealed baseline heterogeneity with R2* rang-
ing fromf5 to 400 second1 (T2*:f2.5–200 milliseconds;
Figure 2). For subgroup 4b (M-CTX), significantly lower
R2* values were found in two tumors on day 7 than on
day 0 (P < .01). However, there was no significant difference
Figure 1. Tumor growth with respect to treatment. Treatment started on the
established AT1 tumors with an average volume of 0.6 cm3 (day 0) and
normalized mean tumor volumes (±SE) are shown for each treatment group.
Group 1 (., control), Group 2 (E, Tha alone), Group 3 ( w , MTD CTX). All six
animals treated with a standard MTD of CTX (150 mg/kg, i.p., twice per week)
died after three doses on or before day 12. Group 4a (o, M-CTX), Group 5a
(5, M-CTX + Tha). M-CTX = metronomic cyclophosphamide given orally in
drinking water.
Figure 2. The R2* map and distribution histogram obtained from a repre-
sentative tumor on day 0 showed significant heterogeneity. R2* ranged from
4.5 to 326 second1 (mean = 51 second1).
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in the mean R2* between days 0 and 7 in the group of six
tumors (Table 1). For subgroup 5b, the mean R2* value
increased significantly on day 1 in one tumor and on day 3
in two other tumors (P < .01) and then returned to pretreat-
ment levels (data not shown), whereas the remaining tumors
showed no significant changes. For the group of six tumors,
there was no significant difference in the mean R2* for any
of the measurements (Table 1). Likewise, untreated control
tumors showed no significant change in R2* over 7 days.
DCE MRI indicated that, in all tumors, pretherapy or post-
therapy, the periphery was better perfused than the center,
with faster and greater signal enhancement and significantly
greater AUC (Figures 3 and 4; Table 2). In control tumors
(Table 2), peripheral perfusion remained similar at each
time, although central response decreased and was signifi-
cantly lower by day 7 (P < .05). Rats receiving M-CTX
(subgroup 4b) or M-CTX + Tha (subgroup 5a) showed a
somewhat similar behavior, with little change in peripheral
perfusion, but a significant decrease in the center on day 7
(P < .001). The histogram of AUC values showed a signifi-
cant shift to the left in both treated groups (Figure 3B). Con-
trol tumors also showed a tendency toward a left shift, but
more subtle and less severe (Figure 3C). When the study was
repeated for M-CTX + Tha–treated tumors (subgroup 5b),
significant changes were found in the tumor centers by day 3,
compared to baseline (day 0) or control animals (Figure 4;
Table 2). On day 7, central regions continued to show highly
significant reduction in AUC (like group 5a), but in this case,
the periphery also indicated significant reduction (Figure 4;
Table 2). Tumors in groups 5a and 5b behaved similarly and
we attribute the level of significance for change in tumor
periphery in group 5b to the smaller variability within tumors
in the group (SE on day 7). When the fraction of AUC < 0.1
observed by DCE MRI on day 7 was plotted versus normal-
ized tumor volume on day 18 (subgroup 5a), a significant
correlation was found (r = 0.85, P < .02; Figure 5).
The results of histologic and immunohistologic studies
are summarized in Table 3. H&E staining showed a huge
central necrosis in the M-CTX– or M-CTX + Tha–treated
tumors after 7 days of treatment (Figure 6), contrasting to
multifocal micronecroses typical of the control R3327-AT1
tumors (52% for M-CTX and 56% for M-CTX + Tha vs 6%
for control, P < .01; Table 2). In other words, M-CTX alone
or combined M-CTX + Tha induced the central necrosis in
these tumors. The CTX + Tha–treated tumors also showed
severe microvascular thromboses (Figures 6 and 8). Immuno-
histochemical staining for caspase-3 showed a significant
increase in apoptotic tumor cells and apoptotic vascular
endothelia (Table 2; Figures 7 and 8). Tumor hypoxia, as
detected by pimonidazole, was also found in much of the
surviving rim in either M-CTX– or M-CTX + Tha–treated
tumors, whereas positive staining in the control tumors
was primarily detected in tumor tissues surrounding micro-
necroses (Figure 7). Intriguingly, overexpression of VEGF
was found in both M-CTX– and M-CTX + Tha–treated
tumor cells, vascular endothelia, and inflammatory cells
(Figures 7 and 8; Table 3). A global colocalization with
hypoxia in the rim of the tumors treated with M-CTX alone
or M-CTX + Tha implies a close relationship between hyp-
oxia and angiogenesis (Figure 7, E and F, I and J ). However,
tumor microvessel density (MVD) showed no significant
difference between the M-CTX–treated (177/mm2) and the
M-CTX + Tha–treated (154/mm2) and control (141/mm2)
tumors (Figure 7, D, H, and L; Table 3).
Discussion
The current study shows significant growth delay in anaplas-
tic Dunning prostate R3327-AT1 tumors by administering
CTX on a continuous low-dose (M-CTX) schedule, alone or
in combination with Tha. Significantly, the data show phys-
iological changes detectable noninvasively by MRI prior to
changes in tumor volume. DCE MRI revealed a significant
decrease in signal enhancement (AUC) starting on day 3 of
treatment through day 7, and a good correlation between
very low AUC (<0.1) on day 7 and tumor growth delay. In
good agreement, histology confirmed that M-CTX alone or
M-CTX + Tha treatment caused a huge central necrotic
core, leaving just a thin peripheral region alive.
There are increasing applications of noninvasive imag-
ing for in vivo tumor diagnosis and prognosis [18,25–27].
Given the noted tumor heterogeneity, and hence observed
heterogeneous responses to treatment, it is vital to be able
to assess early therapeutic response and in turn be able to
individualize treatment regimens. Functional MRI permits
noninvasive evaluation of tumor physiology; thus, MRI may
be a useful tool to detect early treatment– induced changes
prior to overt changes in tumor size. The detection of early
changes following antiangiogenic or vascular targeting treat-
ment may be particularly valuable.
There is increasing interest in using DCE MRI to assess
tumor vascularization in both diagnostic and prognostic
aspects. Strong signal enhancement on T1-weighted images
is reported to correlate with well-vascularized and highly
permeable vessels [16,17]. Indeed, some studies have indi-
cated that DCE MRI is capable of detecting early changes in
tumor vascular perfusion and permeability after treatment
with antiangiogenic or vascular targeting agents [16,17]. In
Table 1. Comparison of R2* Data in the Treated and Control Tumors.
Groups R2* Values (second
1)
Day 0 Day 1 Day 3 Day 7
Mean Range Mean Range Mean Range Mean Range
(1),
Control
(n = 3)
56 ± 2 52–59 55 ± 4 49–61 61 ± 7 49–73 57 ± 5 49–66
(4b),
M-CTX
(n = 6)
65 ± 4 55–81 NA NA 53 ± 4 38–65
(5b)
M-CTX +
Tha
(n = 6)
52 ± 4 39–67 70 ± 7 46–91 64 ± 9 41–102 47 ± 3 39–57
M-CTX: metronomic cyclophosphamide (30 mg/kg per day, p.o.); M-CTX +
Tha: cyclophosphamide (30 mg/kg per day, p.o.) + thalidomide (60 mg/kg,
i.p., twice per week); values are shown as mean ± SE, and range of mean
values; NA: no measurement.
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Figure 3. (A) Signal enhancement (DSI) maps at 60 seconds after infusion of Gd-DTPA-BMA observed from DCE MR images from the central slice of rep-
resentative tumors before (day 0, left) and during treatment (day 7, right). Top row: The M-CTX– treated tumor (subgroup 4b—volumes: day 0 = 0.9 cm3, day 7 =
1.0 cm3). Bottom row: The M-CTX + Tha– treated tumor (subgroup 5a—volumes: day 0 = 0.7 cm3, day 7 = 0.4 cm3). In both of the tumors, significant signal
enhancement after intravenous injection of Gd-DTPA-BMA was seen in the whole section on day 0. However, only a peripheral rim with highly enhancing signal
remained on day 7. (B) Normalized AUC frequency histograms obtained from the three slices of the same tumors showed a significant left shift following therapy
(AUC < 0.1, P < .001). The bins labeled with (#) indicate an AUC of 0.0001 to 0.1. (C) Histograms of a control tumor showed much less shift.
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the present study, we demonstrate that DCE MRI provides
early indication related to the efficacy of M-CTX therapy
(Figure 5). Our results showed a significant decrease in
AUC (tumor perfusion and permeability), especially in central
regions, as early as 3 days after initiating combined M-CTX
+ Tha therapy. Furthermore, tumor size on day 18 is signifi-
cantly associated with weakly enhancing fraction (AUC < 0.1)
on day 7. This is in line with our histologic findings of
increased avascular fractions due to central necrosis for-
mation. These results also parallel a study by Klement et al.
[2], who found that a combination of continuous low-dose
vinblastine and DC101 caused a 65% decrease in tumor
perfusion within 14 days as assessed by histologic analysis
of fluorescent perfusion marker.
Figure 4. Dynamic change in signal intensity – time curve of DCE MRI in a M-CTX + Tha– treated tumor (also shown in Figure 2). T1-weighted images (left column)
showed that the area with lower signal enhancement (blue) progressively increased with time. Like the tumor shown in Figure 3A, the majority of tumor showed little
or no increase in signal enhancement on day 7. Signal versus time curves (right column) revealed differential behavior between peripheral (dark line) and central
(light line) tumor regions observed by DCE MRI.
Table 2. Comparison of DCE MRI Results in the Treated and Control Tumors.
Groups AUC by DCE (mean ± SD)
Day 0 Day 1 Day 3 Day 7
Control (n = 3) Group 1 Periphery 0.71 ± 0.12 0.62 ± 0.12 0.61 ± 0.05 0.63 ± 0.04
Center 0.54 ± 0.06* 0.45 ± 0.01* 0.41 ± 0.05* 0.39 ± 0.02*,y
Whole 0.61 ± 0.05 0.53 ± 0.01 0.53 ± 0.04 0.50 ± 0.06
M-CTX (n = 6) Subgroup 4b Periphery 0.83 ± 0.14 NA NA 0.70 ± 0.12
Center 0.62 ± 0.15* NA NA 0.22 ± 0.08*,z,§
Whole 0.72 ± 0.14 NA NA 0.48 ± 0.10y
M-CTX + Tha (n = 3) Subgroup 5a (n = 7) Periphery 0.81 ± 0.14 NA NA 0.66 ± 0.15
Center 0.63 ± 0.10* NA NA 0.16 ± 0.10*,z,§
Whole 0.71 ± 0.11 NA NA 0.43 ± 0.08y,§
Subgroup 5b (n = 6) Periphery 0.70 ± 0.14 0.61 ± 0.12 0.61 ± 0.09 0.52 ± 0.08y
Center 0.50 ± 0.09* 0.40 ± 0.08* 0.31 ± 0.07*,y,§ 0.19 ± 0.09*,z,§
Whole 0.60 ± 0.13 0.51 ± 0.07 0.49 ± 0.08 0.38 ± 0.07y,§
M-CTX: metronomic cyclophosphamide (30 mg/kg per day, p.o.); M-CTX + Tha: cyclophosphamide (30 mg/kg per day, p.o.) + thalidomide (60 mg/kg, i.p., twice per
week); NA: no measurement.
*P < .005 vs periphery.
yP < .05. vs day 0.
zP < .001 vs day 0.
§P < .05 vs control.
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Qualitative analysis of DCE MRI provides estimates of
tumor perfusion and permeability based on the initial slope
of the time–signal intensity curve or time–concentration
product curve (IAUC) [17,28,29]. In the present study, we
applied a spin-echo multiple slice (SEMS) pulse sequence
with 59 seconds acquisition time and integrated signal
enhancement during the first 3 minutes for AUC analysis,
which gave a lower temporal resolution than some published
studies [17,29]. It is possible that the longer acquisition time
and extended AUC missed information regarding the ‘‘first
pass’’ of the bolus contrast. However, comparison of AUC
estimated over the first 60, 120, or 180 seconds showed
essentially equivalent results. We have previously studied
DCE MRI in the AT1 tumors by using echo planar imaging
with fast acquisition time (4 seconds), which showed similar
heterogeneity between tumor center and periphery [30].
Diverse MRI techniques have previously been used to
study early physiological changes after CTX administered
at the higher conventional dose [28,31,32]. Zhao et al. [31]
found significant changes in apparent diffusion coefficient
(ADC) of water in RIF-1 tumors in mice 2 days after a single
dose of 150 or 300 mg/kg CTX. Poptani et al. [28] reported
an increase in perfusion of RIF-1 tumors in mice 24 hours
after a single dose CTX (300 mg/kg). For the present group
of AT1 tumors, we routinely found significantly decreased
perfusion in central tumor regions within 3 days and in the pe-
riphery by day 7 (Figure 4; Table 2), whereas control tumors
showed no changes in the periphery, but did show change in
the tumor center over 7 days (Table 2). It is critical to note
that the changes are much less apparent when central and
peripheral regions were combined for analysis (Table 2).
BOLD MRI or susceptibility-weighted R2* measurement
exploits the intrinsic paramagnetic properties of deoxy-
hemoglobin. Recently, BOLD MRI has been used to assess
tumor response to antiangiogenesis, vascular targeting, and
photodynamic therapy agents [17,18,33]. An increase in R2*
may relate to increased paramagnetic deoxyhemoglobin in
tumor tissue, which could be caused by a reduction in tissue
perfusion. Some of our treated tumors showed increasedR2*
on days 1 and 3, but with return to baseline or even lower
levels in our final MRI measurements on day 7. The transient
change in R2* may have resulted from decreased vascula-
ture and increased thrombosis. However, tumor R2* is also
related to several other factors (e.g., necrotic tissue devel-
opment) [19]. Overall, R2* neither correlated with growth in
the control group nor with M-CTX or M-CTX + Tha therapy.
Significant increase in tumor apoptosis and evidence of
apoptotic vascular endothelia in this study (Figures 7 and 8;
Table 3) indicated the antiangiogenic effect of M-CTX alone
or M-CTX + Tha. These data coincide with other studies
using antiangiogenic agents [34] or M-CTX [35,36]. There
is increasing evidence that several conventional chemo-
therapeutic agents includingCTX,doxorubicin, vinblastine, and
paclitaxel have potential antiangiogenic activity against ex-
perimental and clinical cancers, especially administered at
continuous low doses [5,37,38]. Furthermore, recent studies
have shown that M-CTX induced thrombospondin 1 expres-
sion, which can further enhance antiproliferative and pro-
apoptotic effects [35,36]. Tha has been recognized as an
antiangiogenic agent, which inhibits neovascularization by
suppressing TNF-a, bFGF, and VEGF production [9,11]. In
addition, clinical studies have shown that Tha, alone or
combined with chemotherapeutic agents, caused vascular
thromboses [39]. In the current study, we found increased
thromboses in microvessels of treated tumors, compared
with control tumors.
We observed a significant increase in VEGF expression
in the tumors treated with M-CTX or M-CTX + Tha, as also
reported in studies of several other antiangiogenic agents
(e.g., TNP-470 and SU6668) [16,34]. Colocalization of
VEGF overexpression with hypoxia (pimonidazole staining;
Figure 7) supports the hypothesis that tumor hypoxia may
have mediated a feedback or compensatory increase of
VEGF. Poptani et al. [28] recently reported that RIF-1 fibro-
sarcoma treated with a single dose of CTX, 300 mg/kg, i.p.,
showed a significant decrease in tissue pO2 24 hours after
treatment. The decrease in glycolytic rates and increase in
oxidative metabolism observed in their study suggest that
hypoxia resulted from more oxygen consumption by surviv-
ing cells rather than shortage of oxygen supply [32]. In our
current study, MVD evaluation by the ‘‘hot spot’’ technique
revealed no significant change in vasculature of the tumor
periphery between the treated and pretreated tumors or
Figure 5. A significant correlation (r = 0.85, P < .02) was found between
normalized tumor volume on day 18 and the fraction of poorly DCE-
enhancing tumor (AUC < 0.1) on day 7 in the seven M-CTX + Tha– treated
(group 5a) tumors.
Table 3. Evaluation of Antitumor Effects by Histology.
Groups H&E
Necrosis
(%)
Apoptosis
Caspase-3
(%)
Hypoxia
Pimonidazole
(%)
Angiogenesis
VEGF
(%)
MVD
CD31
(mm2)
(1) Control
(n = 3)
6 ± 1 3 ± 1 15 ± 3 4 ± 2 141 ± 15
(4b) M-CTX
(n =3)
52.7* 16 ± 4y 64.3* 60 ± 8* 177 ± 11
(5b) M-CTX +
Tha (n = 3)
56.6* 14 ± 3y 78 ± 4* 66 ± 6* 154 ± 17
M-CTX: metronomic cyclophosphamide (30 mg/kg per day, p.o.); M-CTX +
Tha: cyclophosphamide (30 mg/kg per day, p.o.) + thalidomide (60 mg/kg,
i.p. twice per week); MVD: microvascular density.
*P < 0.01 from control.
yP < 0.05 from control.
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Figure 6. H&E staining of whole mount sections of M-CTX– and M-CTX + Tha– treated tumors, compared with a size-matched control tumor (A). For the M-CTX–
treated (B) and M-CTX + Tha– treated (C) tumors, a large central necrosis was obvious on day 7; only a very thin rim with viable tissue was seen on day 42 of the
M-CTX + Tha tumor (D). Enlarged image (10) for the area selected from (C) shows a border region between the necrotic and viable tissues (E). Significant
increase in the size of nuclei and cells indicates an inhibition of tumor mitosis. An increased number of vascular thromboses was identified in the tumors treated
with M-CTX + Tha (F). Bar: 100 m.
Figure 7. After 7 days of treatment, immunohistology showed a significant increase in tumor hypoxia, VEGF expression, and apoptosis in both the M-CTX– treated
(middle, E–G) and the M-CTX + Tha– treated (bottom, I –K) tumors, compared with untreated controls (top, A–C). There was no significant change in MVD (D
versus H versus L). Colocalization of tumor hypoxia and VEGF expression in the M-CTX– treated (E and F) and M-CTX + Tha– treated (I and J) tumors was seen
in the two adjacent tissue sections. Bar: 100 m.
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size-matched controls (Figure 7). However, the overall frac-
tion of vasculature decreased significantly and resulted in a
huge avascular central necrotic area, evidenced by both
histology and MRI, as also reported for other antiangio-
genic studies [16]. Important to this observation is the fact
that AT1 tumors do not normally develop a central necrosis
[21–23,40]. In terms of tumor growth delay, M-CTX, alone
or combined with Tha, significantly increased tumor volume
doubling time (Figure 1). Compared with the M-CTX alone,
the combination with Tha in this study had an additional
inhibitory effect on tumor growth, although the effect of Tha
appears to be, at best, additional rather than synergistic.
However, a recent phase II study conducted by NCI [41]
concluded that adding Tha to docetaxel resulted in an en-
couraging PSA decline rate and overall median survival rate
in patients with metastatic AIPC. Another phase II trial [42]
also suggests that low-dose Tha (100 mg/kg, daily) may be
an option for patients with AIPC. Others reported that this
continuous low-dose regimen, if combined with other thera-
peutic approaches (e.g., antiangiogenesis or immunother-
apy), could produce a synergistic effect in a variety of
experimental tumors [3,4]. The mode of action of Tha is
complicated and its antiangiogenic effect is believed to be
at least partly independent of VEGF. This might explain that
the level of VEGF overexpression, accompanied with M-CTX
treatment– induced hypoxia, was not reduced in theM-CTX +
Tha group. Metronomic therapy has also been shown to be
effective at overcoming drug resistance [6]. In the future, it
would be interesting to develop sublines of the Dunning
prostate R3327 tumor resistant to traditional CTX doses
and to investigate whether the metronomic approach would
still be effective. Our higher dose CTX (150 mg/kg) schedule,
which is equivalent to the clinical MTD dose, induced sig-
nificant tumor growth delay during the first 12 days of treat-
ment, but all six animals died after three doses. A similar
observation has been reported by Man et al. [3] that mice
with MDA-MB-231 breast tumor xenografts died after three
doses of 150mg/kg CTX. Reduced toxicity of continuous low-
dose therapy could be an important advantage and, recently,
the combination of metronomic CTX with methotrexate has
been reported to have a significant response in patients
with advanced or recurrent breast carcinoma [5].
In summary, continuous low-dose CTX, alone or com-
bined with Tha, significantly inhibited tumor growth of the
syngeneic rat prostate R3327-AT1 tumor with reduced tox-
icity compared with multiple conventional doses. Our results
demonstrate that physiological changes in the early stage
of this low-dose regimen can be detected by MRI. MRI
revealed intratumoral heterogeneity in situ and in vivo, and
changes in temporo-spatial dynamics, which may give an
early indication of treatment response and ultimately allow
scheduling, dosage, and drug combination to be optimized
and individualized.
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Figure 8. M-CTX + Tha– induced elevated VEGF and endothelial apoptosis. A region of VEGF staining enlarged from Figure 6A (A). The positive VEGF staining
was detected in tumor cells (cytoplasm and nuclei), vascular endothelium (arrow), and infiltrated inflammatory cells (arrow head). Detached endothelial cells from
basement membrane were positively stained for apoptosis using anti –active caspase-3 (arrow) (B). A typical perivascular cuff was seen in regions surrounding an
embolized microvessel resulting in tumor necrosis outside the cuff (C) and apoptosis in the cuff (arrows) (D). Bar: 100 m.
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